Direct hit on FGFR3: BridgeBio’s infigratinib matches Voxzogo on height, adds oral option

Data announced this week from BridgeBio suggests directly inhibiting the overactive FGFR3 receptor — the root driver of achondroplasia — can achieve efficacy comparable to the current standard of care, while offering an oral alternative to daily injections. The company is planning regulatory submissions for the second half of 2026.

Achondroplasia, a genetic form of dwarfism, is caused by activating mutations in the FGFR3 gene (most commonly G380R) that inhibit proliferation and differentiation of chondrocytes, the cells in the growth plates of limb bones. The result is impaired bone growth that leads to a disproportionate and short stature...